Moxetumomab is a monoclonal antibody targeting CD22, which can be used to synthesise the antibody-drug conjugate (ADC) Moxetumomab pasudotox for the study of hairy cell leukaemia (HCL).
Purity:
95%
CAS Number:
[1622075-65-3]
Target:
Immunology/Inflammation related|||ADC Antibody
* VAT and and shipping costs not included. Errors and price changes excepted